Systemic treatment of liver metastases from colorectal cancer

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 3, 2013, Pages 193-203

  Stein, Alexander ^a   Schmoll, Hans Joachim ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

colorectal liver metastases; induction treatment; perioperative; resectability

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; LIVER METASTASIS; NEUROTOXICITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

EID: 84879307821     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012473347     Document Type: Review

References (73)

1. Adam R. Barroso E. (2011) Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. J Clin Oncol 29(Suppl.): abstract 3519.
2. Adam R. de Haas R. Wicherts D. Aloia T. Delvart V. Azoulay D. et al. (2008) Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 26: 3672–3680.
3. Allegra C. Yothers G. O'Connell M. Sharif S. Petrelli N. Colangelo L. et al. (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11–16.
4. Aloia T. Sebagh M. Plasse M. Karam V. Levi F. Giacchetti S. et al. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983–4990.
5. Assenat E. Desseigne F. Thezenas S. Viret F. Mineur L. Kramar A. et al. (2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16: 1557–1564.
6. Benoist S. Brouquet A. Penna C. Julie C. El Hajjam M. Chagnon S. et al. (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939–3945.
7. Benoist S. Nordlinger B. (2009) The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol 16: 2385–2390.
8. Blazer D. III Kishi Y. Maru D. Kopetz S. Chun Y. Overman M. et al. (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344–5351.
9. Bokemeyer C. Bondarenko I. Hartmann J. de Braud F. Schuch G. Zubel A. et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535–1546.
10. Bokemeyer C. Cutsem E. Rougier P. Ciardiello F. Heeger S. Schlichting M. et al. (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466–1475.
11. Bruera G. Santomaggio A. Cannita K. Baldi P. Tudini M. de Galitiis F. et al. (2010) ‘Poker’ association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 10: 567.
12. de Gramont A. van Cutsem E. et al. (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13 (12): 1225–1233.
13. de Haas R. Wicherts D. Flores E. Azoulay D. Castaing D. Adam R. (2008) R 1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248: 626–637.
14. de Jong M. Pulitano C. Ribero D. Strub J. Mentha G. Schulick R. et al. (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250: 440–448.
15. Douillard J. Siena S. (2011) Final results from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX 4 for firstline metastatic colorectal cancer (mCRC). J Clin Oncol 29(Suppl.): abstract 3510.
16. Erinjeri J. Fong A. Kemeny N. Brown K. Getrajdman G. Solomon S. (2011) Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117: 1296-1301.
17. Falcone A. Ricci S. Brunetti I. Pfanner E. Allegrini G. Barbara C. et al. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670–1676.
18. Ferlay J. Shin H. Bray F. Forman D. Mathers C. Parkin D. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
19. Folprecht G. Gruenberger T. (2012) Survival with cetuximab / FOLFOX or cetuximab / FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study. J Clin Oncol 30(Suppl. 4): abstract 540.
20. Folprecht G. Gruenberger T. Bechstein W. Raab H. Lordick F. Hartmann J. et al. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38–47.
21. Fong Y. Fortner J. Sun R. Brennan M. Blumgart L. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309–318; discussion: 318–321.
22. Garufi C. Torsello A. Tumolo S. Ettorre G. Zeuli M. Campanella C. et al. (2010) Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103: 1542–1547.
23. Gaujoux S. Goere D. Dumont F. Souadka A. Dromain C. Ducreux M. et al. (2011) Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? Dig Surg 28: 114–120.
24. Gruenberger B. Tamandl D. Schueller J. Scheithauer W. Zielinski C. Herbst F. et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26: 1830–1835.
25. Hecht J. Mitchell E. Chidiac T. Scroggin C. Hagenstad C. Spigel D. et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672–680.
26. Hughes K. Simon R. Songhorabodi S. Adson M. Ilstrup D. Fortner J. et al. (1986) Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100: 278–284.
27. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
28. Jemal A. Bray F. Center M. Ferlay J. Ward E. Forman D. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
29. Karagkounis G. Torbenson M. (2012) Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. J Clin Oncol 30: abstract 3616.
30. Karoui M. Penna C. Amin-Hashem M. Mitry E. Benoist S. Franc B. et al. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243: 1–7.
31. Kemeny N. Fong Y. (2012) Is conversion to resection possible with hepatic arterial infusion (HAI) and systemic (SYS) even in previously treated patients (pts) with unresectable colorectal liver metastases (UnCLM)? J Clin Oncol 30: abstract 3577.
32. Kesmodel S. Ellis L. Lin E. Chang G. Abdalla E. Kopetz S. et al. (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26: 5254–5260.
33. Kishi Y. Zorzi D. Contreras C. Maru D. Kopetz S. Ribero D. et al. (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17: 2870–2876.
34. Klinger M. Tamandl D. Eipeldauer S. Hacker S. Herberger B. Kaczirek K. et al. (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17: 2059–2065.
35. Kopetz S. Chang G. Overman M. Eng C. Sargent D. Larson D. et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677–3683.
36. Langer B. Bleiberg H. Labianca R. et al. (2002) Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 21: 2002 (abstract 592).
37. Lonardi S. Fornaro L. (2012) Phase II study of panitumumab (P) in combination with FOLFOXIRI as first-line treatment of metastatic colorectal cancer (mCRC): activity in molecularly selected patients (pts). J Clin Oncol 30: abstract 3555.
38. Mantke R. Schmidt U. Wolff S. Kube R. Lippert H. (2012) Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur J Surg Oncol 38: 259–265.
39. Masi G. Loupakis F. Salvatore L. Fornaro L. Cremolini C. Cupini S. et al. (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11: 845–852.
40. Maughan T. Adams R. Smith C. Meade A. Seymour M. Wilson R. et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103–2114.
41. Mitry E. Fields A. Bleiberg H. Labianca R. Portier G. Tu D. et al. (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906–4911.
42. Morris E. Forman D. Thomas J. Quirke P. Taylor E. Fairley L. et al. (2010) Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97: 1110–1118.
43. Nakano H. Oussoultzoglou E. Rosso E. Casnedi S. Chenard-Neu M.P. Dufour P. et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118–124.
44. Nordlinger B. Sorbye H. (2012) EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. J Clin Oncol 30(Suppl.): abstract 3508.
45. Nordlinger B. Sorbye H. Glimelius B. Poston G. Schlag P. Rougier P. et al. (2008) Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007–1016.
46. Nordlinger B. van Cutsem E. Gruenberger T. Glimelius B. Poston G. Rougier P. et al. (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20: 985–992.
47. Portier G. Elias D. Bouche O. Rougier P. Bosset J.F. Saric J. et al. (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCDACHBTH AURC 9002 trial. J Clin Oncol 24: 4976–4982.
48. Poston G. Figueras J. Giuliante F. Nuzzo G. Sobrero A. Gigot J. et al. (2008) Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 26: 4828–4833.
49. Price T. Hardingham J. Lee C. Weickhardt A. Townsend A. Wrin J. et al. (2011) Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29: 2675–2682.
50. Pulitano C. Bodingbauer M. Aldrighetti L. Choti M. Castillo F. Schulick R. et al. (2012) Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol 19: 435–442.
51. Ribero D. Wang H. Donadon M. Zorzi D. Thomas M. Eng C. et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761–2767.
52. Rubbia-Brandt L. Giostra E. Brezault C. Roth A. Andres A. Audard V. et al. (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299–304.
53. Saltz L. Clarke S. Diaz-Rubio E. Scheithauer W. Figer A. Wong R. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013–2019.
54. Saltz L. Niedzwiecki D. Hollis D. Goldberg R. Hantel A. Thomas J. et al. (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456–3461.
55. Salvatore L. Loupakis F. (2012) FOLFOXIRI plus bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. J Clin Oncol 30: abstract 3585.
56. Schmoll H. Sargent D. (2007) Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 370: 105–107.
57. Schmoll H. van Cutsem E. Stein A. Valentini V. Glimelius B. Haustermans K. et al. (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: 2479–2516.
58. Tanaka K. Nojiri K. Kumamoto T. Takeda K. Endo I. (2011) R 1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. Eur J Surg Oncol 37: 336–343.
59. Teng H. Huang Y. Lin J. Chen W. Lin T. Jiang J. et al. (2012) BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 106: 123–129.
60. Tol J. Koopman M. Cats A. Rodenburg C. Creemers G. Schrama J. et al. (2009 b) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563–572.
61. Tol J. Nagtegaal I. Punt C. (2009 a) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98–99.
62. van Cutsem E. Dicato M. Arber N. Berlin J. Cervantes A. Ciardiello F. et al. (2010) Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO / World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 21(Suppl. 6): vi1–vi10.
63. van Cutsem E. Kohne C. Lang I. Folprecht G. Nowacki M. Cascinu S. et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019.
64. van Cutsem E. Labianca R. Bodoky G. Barone C. Aranda E. Nordlinger B. et al. (2009) Randomized phase III trial comparing biweekly infusional fluorouracil / leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27: 3117–3125.
65. van der Pool A. Damhuis R. Ijzermans J. de Wilt J. Eggermont A. Kranse R. et al. (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14: 56–61.
66. Vauthey J. Pawlik T. Ribero D. Wu T. Zorzi D. Hoff P. et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065–2072.
67. Voest E. Snoeren N. (2011) A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol 29(Suppl.): abstract 3565.
68. Wicherts D. de Haas R. Sebagh M. Saenz Corrales E. Gorden D. Levi F. et al. (2011) Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 98: 399–407.
69. Wong R. Cunningham D. Barbachano Y. Saffery C. Valle J. Hickish T. et al. (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22: 2042–2048.
70. Yamaguchi T. Mori T. Takahashi K. Matsumoto H. Miyamoto H. Kato T. (2008) A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology 55: 173–178.
71. Ychou M. Hohenberger W. Thezenas S. Navarro M. Maurel J. Bokemeyer C. et al. (2009 a) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964–1970.
72. Ychou M. Raoul J. Douillard J. Gourgou-Bourgade S. Bugat R. Mineur L. et al. (2009 b) A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20: 674–680.
73. Ychou M. Viret F. Kramar A. Desseigne F. Mitry E. Guimbaud R. et al. (2008) Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 62: 195–201.